Lexaria Bioscience Corp. (LEXX) Stock Price & Analysis
Lexaria Bioscience Corp. (LEXX) closed at USD 2.99 on Thursday, October 15, 2026, up 6.03% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.99; the Oct 15, 2026 session ranged USD 2.74–3.11 on volume of 32,487 shares. Market capitalization is —, with a 52-week range of USD 2.43–21.6 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LEXX.md
Key facts (LEXX)
- Analysts: None (1 analysts), mean target USD 82.5 (range 82.5–82.5).
- Total return with dividends: 1Y -75.8% vs S&P 500 +18.1%; 5Y -97.1% vs S&P 500 +85.1%.
Analysts (LEXX)
Consensus None, 1 analysts; mean target USD 82.5 (low 82.5, high 82.5).
Total return (dividends reinvested) (LEXX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -75.8% | -97.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -76.0% | -50.6% |
| Volatility (annualized) | 134.6% | 118.5% |
| Max drawdown | -86.2% (Dec 2025→Oct 2026) | -97.2% (Oct 2021→Sep 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 2.99 |
|---|---|
| Change | ▲ 6.03% (up) |
| Previous Close | USD 2.99 |
| Open | USD 2.99 |
| Day Range | USD 2.74 – 3.11 |
| 52-Week Range | USD 2.43 – 21.6 |
| Volume | 32,487 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (LEXX)
Nexqual's technical model rates LEXX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.86 (neutral) |
| vs SMA50 | Below (USD 6.39) |
| MACD | -0.9 (negative) |
Analyst Ratings (LEXX)
Wall Street analysts rate LEXX "None" based on 1 analysts, with a mean price target of USD 82.5 (range USD 82.5–82.5), per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 82.5 |
| High Target | USD 82.5 |
| Low Target | USD 82.5 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (LEXX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-05-31 | USD -1.2 vs est -0.9 ▼ miss |
| 2026-02-28 | USD -0.9 vs est -1.05 ▲ beat |
| 2025-11-30 | USD -1.05 vs est -1.95 ▲ beat |
| 2025-08-31 | USD -1.95 vs est -2.35 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (LEXX)
| Total Revenue | $194,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -3862.94% |
| Profit Margin | +0.00% |
| ROE | -162.77% |
| Debt / Equity | 0.02 |
| Current Ratio | 10.6 |
| Total Cash | $3.62M |
| Total Debt | $86,714 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (LEXX)
Nexqual rates Lexaria Bioscience Corp.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Strong — Revenue +52% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -163%, ROA -81.3% |
Ownership (LEXX)
| Insider Ownership | +3.32% |
|---|---|
| Institutional Ownership | +6.52% |
| Shares Outstanding | 2.11M |
| Float | 1.60M |
| Short % of Float | +13.43% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (LEXX)
Lexaria Bioscience Corp. is led by Richard C. Christopher (age 55), CEO & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| CEO & Director | Richard C. Christopher (age 55) |
|---|---|
| Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director | John M. Docherty M.Sc. (age 56) |
| Chief Financial Officer | Michael Shankman (age 64) |
| Director of Operations | Kristin Hamilton |
Major Backers & Investors (LEXX)
Notable institutional backers of Lexaria Bioscience Corp. include Invenomic Capital Management, LP, Fidelity, Citadel, according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invenomic Capital Management, LP | 1.09% |
| Fidelity | 0.62% |
| Citadel | 0.5% |
| Toronto Dominion Bank | 0.32% |
| NORTHERN LIGHTS FUND TRUST II-Invenomic Fund | 0.32% |
| HRT Financial LP | 0.21% |
| UBS Group AG | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.18% |
| Geode Capital | 0.79% |
| Northern Trust | 0.13% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt